Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pozdeutinurad - Arthrosi Therapeutics Australia

Next Previous
Drug Profile

Pozdeutinurad - Arthrosi Therapeutics Australia

Alternative Names: AR-882

Latest Information Update: 29 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arthrosi Therapeutics Australia
  • Developer Arthrosi Therapeutics; Arthrosi Therapeutics Australia; Guangzhou Ruianbo Pharmaceutical Technology
  • Class Antigouts; Small molecules; Uricosurics
  • Mechanism of Action SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gout
  • Phase II/III Hyperuricaemia

Most Recent Events

  • 20 Aug 2025 Arthrosi Therapeutics announced the intention to submit NDA for Gout
  • 20 Aug 2025 Arthrosi Therapeutics completes enrolment in a phase III trial for Gout in the US (PO) (NCT06846515)
  • 20 Aug 2025 Arthrosi Therapeutics plans a phase II trial for Gout (Combination therapy, Treatment experienced) (PO, Capsule) in September 2025 (NCT07116746)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top